APT-POCT-01: An Open Label, Pharmacokinetic Study of Plasma/Urine/Salivary Drug Concentrations Over Fourteen Days Following Drug Intake Cessation, In HIV-Uninfected Healthy Volunteers Dosing to Steady-state to Further Development of Point of Care Diagnostic Testing
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Lamivudine (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms APTAMER
Most Recent Events
- 02 Mar 2022 Status changed from active, no longer recruiting to completed.
- 17 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2020 Status changed from not yet recruiting to recruiting.